Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Practice Management

Severe Illness, Death Reported With Misuse of Non-Pharmaceutical Chloroquine for COVID-19 “Prevention”

Diana Ernst, RPh

April 1, 2020

The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”

Multiple Sclerosis

Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis

Diana Ernst, RPh

March 30, 2020

The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.

Practice Management

FDA Issues Statement Regarding NSAID Use and COVID-19

Diana Ernst, RPh

March 23, 2020

The Food and Drug Administration has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs in patients with coronavirus disease 2019.

Multiple Sclerosis

Ponesimod NDA for Relapsing Multiple Sclerosis Submitted for Review

Diana Ernst, RPh

March 23, 2020

The New Drug Application for ponesimod has been submitted to the Food and Drug Administration for the treatment of relapsing multiple sclerosis.

Neurobehavioral Disorders

FDA Bans Electrical Stimulation Devices for Self-Injurious, Aggressive Behavior

Diana Ernst, RPh

March 16, 2020

The use of electrical stimulation devices to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration.

Neurobehavioral Disorders

Troriluzole No Better Than Placebo in Generalized Anxiety Disorder Study

Diana Ernst, RPh

February 20, 2020

Results showed a mean change from baseline of -9.28 points (95% CI, -10.23 to -8.32) on the HAM-A total score in patients treated with troriluzole compared with -9.35 points (95% CI, -10.34 to -8.36) with placebo (P =.917).

Epilepsy

Vigabatrin Approved for Younger Patients With Complex Partial Seizures

Diana Ernst, RPh

January 30, 2020

The FDA has expanded the approval of vigabatrin to include treatment of refractory complex partial seizures in patients aged 2 to <10 years of age.

Pain

FDA Panels Vote “No” on Oxycodone Extended-Release Tablets

Diana Ernst, RPh

January 22, 2020

Safety and efficacy was based on demonstration of bioequivalence to Oxycontin.

Pain

FDA Committees Vote on Novel Opioid for Chronic Low Back Pain

Diana Ernst, RPh

January 16, 2020

As a result of the vote, Nektar has decided to withdraw the New Drug Application for oxycodegol and to cease further development of the product.

Epilepsy

Diazepam Nasal Spray Approved for Seizure Clusters

Diana Ernst, RPh

January 15, 2020

The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

Next post in Epilepsy